Scientific Writing Guidelines For The Korean FDA (MFDS)

Scientific writing plays a pivotal role in the regulatory approval process in South Korea, particularly for pharmaceuticals, biologics, nutraceuticals, and health functional products. The Ministry of Food and Drug Safety (MFDS) enforces stringent standards to ensure that all submitted scientific documents demonstrate accuracy, transparency, reproducibility, and regulatory compliance.

For global manufacturers and regulatory professionals, understanding MFDS scientific writing requirements, Common Technical Document (CTD) structure, and clinical documentation standards are critical for achieving successful product approvals. This 2026 guide by Maven Regulatory Solutions outlines best practices, regulatory expectations, and advanced strategies for high-quality scientific submissions.

Understanding The MFDS Regulatory Framework

The MFDS regulates:

• Pharmaceuticals and biologics 
• Health functional foods (nutraceuticals) 
• Medical devices and combination products 

The agency aligns closely with ICH (International Council for Harmonisation) guidelines, emphasizing:

• Data integrity and traceability 
• Standardized dossier formats (CTD/eCTD) 
• Evidence-based evaluation of safety and efficacy 

Core Principles of Scientific Writing For MFDS

Effective regulatory medical writing for MFDS must adhere to the following principles:

• Clarity: Use precise and unambiguous language 
• Consistency: Maintain uniform terminology across all modules 
• Accuracy: Ensure all scientific data is validated and referenced 
• Completeness: Provide comprehensive supporting documentation 
• Regulatory Alignment: Follow MFDS and ICH formatting standards 

Key Documentation Requirements for MFDS Submissions

Scientific writing must support multiple regulatory documents required for approval:

1. Clinical Trial Documentation

• Clinical Trial Protocol (study design, endpoints, methodology) 
• Investigator’s Brochure (IB) 
• Case Report Forms (CRFs) 
• Clinical Study Reports (CSR) 

2. Nonclinical & Investigational Data

• Pharmacology studies 
• Toxicology reports (acute, sub-chronic, chronic toxicity) 
• ADME (Absorption, Distribution, Metabolism, Excretion) data 

3. Chemistry, Manufacturing, and Controls (CMC)

• Drug substance and product characterization 
• Stability studies 
• Manufacturing process validation 

4. Regulatory Declarations

• Informed consent documentation 
• Good Clinical Practice (GCP) compliance statements 
• Ethical approvals 

Structured Format for MFDS Scientific Documents

MFDS expects all submissions to follow a standardized manuscript and CTD structure:

MFDS Labeling and Regulatory Writing Requirements

Accurate labeling is a critical component of drug approval in South Korea.

Mandatory Labeling Elements

• Product name and dosage strength 
• Indications and therapeutic use 
• Dosage and administration guidelines 
• Contraindications and warnings 
• Adverse drug reactions (ADR) 
• Storage conditions and self-life 

All labeling content must be:

• Translated into Korean
• Scientifically consistent with submitted data
• Aligned with MFDS-approved claims

Ethical And Compliance Considerations

Scientific writing must demonstrate strict adherence to ethical standards:

• Institutional Review Board (IRB) approval for human studies 
• Animal study compliance with GLP standards 
• Patient confidentiality and data protection 
• Transparent reporting of risks and adverse events 

Failure to meet ethical standards can result in submission rejection or regulatory delays.

Advanced Scientific Writing Best Practices 

To improve approval success rates, regulatory writers should incorporate:

1. CTD & eCTD Optimization

• Use structured modules (Module 1–5) 
• Ensure cross-referencing across sections 
• Maintain digital submission readiness 

2. Data Standardization

• Use globally accepted formats (CDISC for clinical data) 
• Maintain consistency between clinical and nonclinical sections 

3. Risk-Based Writing Approach

• Highlight benefit-risk analysis 
• Address potential regulatory concerns proactively 

4. Integration Of Real-World Evidence (RWE)

• Increasing acceptance in MFDS submissions 
• Supports post-market safety and effectiveness 

Common Challenges in MFDS Scientific Writing

MFDS Review Process and Evaluation Criteria

The MFDS evaluates submissions based on:

• Scientific validity of data 
• Compliance with regulatory guidelines 
• Risk-benefit profile 
• Quality and clarity of documentation 

Well-structured and precise scientific writing significantly reduces review cycles and accelerates approval timelines.

Latest 2026 Updates in MFDS Scientific Writing

• Increased emphasis on digital submissions (eCTD format) 
• Enhanced scrutiny on data transparency and traceability 
• Inclusion of AI-supported data analysis (emerging trend)
• Stronger requirements for pharmacovigilance documentation
• Alignment with global harmonization standards (ICH E6 R3 updates) 

Why Choose Maven Regulatory Solutions?

Maven Regulatory Solutions delivers expert support to:

• Regulatory medical writing for MFDS submissions 
• CTD and eCTD dossier preparation 
• Clinical and non-clinical documentation 
• Labeling compliance and localization 
• End-to-end regulatory strategy for South Korea 

Our expertise ensures high-quality, compliant, and approval-ready scientific documentation.

Conclusion

Scientific writing is a cornerstone of successful MFDS regulatory submissions. From clinical trial documentation and CTD structuring to ethical compliance and labeling requirements, every component must meet stringent regulatory standards.

With evolving MFDS requirements in 2026, adopting a strategic, structured, and compliant scientific writing approach is essential for accelerating approvals and ensuring long-term success in the South Korean market.

FAQs 

1. What are MFDS scientific writing guidelines?

They are regulatory standards for preparing scientific and clinical documents required for product approval in South Korea.

2. Does MFDS follow CTD format?

Yes, MFDS follows the Common Technical Document (CTD) structure aligned with ICH guidelines.

3. Is Korean translation mandatory?

Yes, all labeling and key documents must be submitted in Korean.

4. What is the role of clinical study reports (CSR)?

CSR provides detailed clinical trial data supporting safety and efficacy.

5. How can companies improve MFDS approval success?

By ensuring high-quality scientific writing, regulatory compliance, and complete documentation.